The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. The major factors driving the growth of this market are the increasing adoption of oligonucleotides in therapeutics and the rising funding and support provided by the government for synthetic biology research.
The players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan), Biolegio B.V (Netherlands), Biolytic Lab Performance Inc. (US), Microsynth AG (Switzerland), Adtbio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Biogen Inc. (US) Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), and Alnylam Pharmaceuticals, Inc. (US).
To know about the assumptions considered for the study download the pdf brochure
DANAHER CORPORATION (US)
Danaher has become one of the key players in the oligonucleotide synthesizers market with the acquisition of IDT (2018) and Cytiva (2020). These acquisitions enabled Danaher to expand its product portfolio for oligonucleotide synthesis. The company now offers synthesized oligos, such as primers & probes, and the raw materials used to synthesize oligos, such as reagents and equipment. IDT pursues organic strategies such as product launches and expansions as its key growth strategies. For instance, in 2019, the company launched the longest (up to 350 nucleotides in length) ready-to-use custom oligo pools in the market. In 2020, the company also opened a new business entity in China to better serve its regional customer base. Such strategic developments help the company further enhance its presence and increase its share in the oligonucleotide synthesis market.
THERMO FISHER SCIENTIFIC, INC. (US)
Thermo Fisher Scientific (US) led the oligonucleotide synthesis market with the second-largest share in 2020. The company has an exhaustive product portfolio consisting of primers, probes, custom oligos, phosphoramidites, reagents, and custom oligo modification. The company operates in over 50 countries across North America, Europe, Asia, and Latin America. It has adopted various organic and inorganic growth strategies to strengthen its market position. For instance, in 2019, Thermo Fisher supported BioNTech’s (Germany) messenger RNA (mRNA) manufacturing platform by supplying nucleotides, enzymes, reagents, and other critical raw materials to expand its manufacturing capacities.
BIOGEN, INC. (US)
Biogen led the oligonucleotide synthesis therapeutics market with the largest share in 2021. This large share can be attributed to the launch of SPINRAZA in 2016. SPINRAZA is the first and only approved treatment for SMA (spinal muscular atrophy). The company has its oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is utilized for manufacturing antisense oligonucleotide drugs like SPINRAZA and other antisense oligonucleotide drug candidates, which are currently in the pipeline. Globally, SPINRAZA’s revenue reached USD 2 billion in 2020. SPINRAZA consistently accounted for more than 10% of Biogen’s total revenue for the past three years. The company mainly focuses on growth strategies such as expansions. For instance, in 2019, SPINRAZA (nusinersen) received approval from the China National Medical Products Association (NMPA) for the treatment of 5q SMA, which further expanded its presence in China.
Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User (Pharma, CROS, CMOs) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE